logo-loader
viewHemoGenyx Pharmaceuticals

HemoGenyx CEO says progress 'definitely surpassing expectations'

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), tells Proactive Investors they've entered into a collaboration agreement with Rockefeller University to use their new type of humanised mice for autoimmune disease modelling in an effort to develop new treatment for autoimmune diseases, specifically Lupus.

The first stage of development work will create mice that emulate the human symptoms of Lupus, while the second stage will then focus on the development of multi-specific antibodies and cell therapies to treat the disease in these mice.

Quick facts: HemoGenyx Pharmaceuticals

Price: 2 GBX

LSE:HEMO
Market: LSE
Market Cap: £7.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read